12.49  -1.2 (-8.77%)		02-27 16:00
Open: 13.49 High: 13.53 Volume: 33,456		Pre. Close: 13.69 Low: 12.49 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	16.92	1-year :	19.27
Resists	First :	14.49	Second :	16.5
Pivot price	13.52
Supports	First :	11.24	Second :	9.35
MAs	MA(5) :	13.57	MA(20) :	13.55
	MA(100) :	9.73	MA(250) :	162.44
MACD	MACD :	0	Signal :	0.2
%K %D	K(14,3) :	46.7	D(3) :	50.8
RSI	RSI(14): 46
52-week	High :	2235	Low :	2.88

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PLRZ ] has closed above bottom band by 5.4%. Bollinger Bands are 67% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	13.81 - 13.88	13.88 - 13.94
Low:	12.78 - 12.85	12.85 - 12.92
Close:	13.57 - 13.68	13.68 - 13.8

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Thu, 26 Feb 2026
Polyrizon (Nasdaq: PLRZ) reports enhanced naloxone nasal deposition study - Stock Titan

Thu, 26 Feb 2026
Lab test: Polyrizon nasal naloxone hits target area 94.6% vs 79.6% - Stock Titan

Mon, 23 Feb 2026
PLRZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Tue, 17 Feb 2026
Drug-free nasal spray NASARIX is designed to trap allergy triggers - Stock Titan

Tue, 17 Feb 2026
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker - Yahoo Finance

Tue, 13 Jan 2026
Debt-free biotech Polyrizon hunts revenue in AI, aviation and defense - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	19.9 (%)
Held by Institutions	0.9 (%)
Shares Short	51 (K)
Shares Short P.Month	130 (K)

EPS	-1.23
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	18.75
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-22.3 %
Return on Equity (ttm)	-12.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.01
Qtrly Earnings Growth	0 %
Operating Cash Flow	-3 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-10.44
PEG Ratio	0
Price to Book value	0.67
Price to Sales	0
Price to Cash Flow	-5.04

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.